Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Core Insights - Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer, effective January 2, 2026, to oversee clinical development and medical strategy for Olvi-Vec [2][3] Company Overview - Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [8] - The company is advancing Olvi-Vec through multiple pivotal clinical trials, including a Phase 3 trial for platinum-resistant ovarian cancer and a Phase 2 trial for non-small-cell lung cancer [8] Leadership Experience - Dr. Litten has over 20 years of experience in oncology drug development, having held senior roles at various biopharmaceutical companies, including Chimeric Therapeutics and Artiva Biotherapeutics [4][5] - His expertise includes leading clinical trials across liquid and solid tumors, with a focus on innovative therapies [3][4] Clinical Development Strategy - Dr. Litten's appointment is expected to enhance Genelux's clinical execution and support the development of Olvi-Vec as a leading immunotherapy option [3][6] - The company aims to unlock the full clinical and commercial potential of Olvi-Vec, which is seen as a compelling therapeutic platform for multiple tumor types [6] Stock Option Award - In connection with his appointment, Dr. Litten received a stock option award to purchase 275,000 shares of common stock, which will vest over four years [7]